Friday, 7. 10. 2016    

Cancer Cell Research (Online ISSN: 2161-2609)


Current Issue

Vol.3  No.12


Article: B7-H1 Blockade Enhanced the Function of Peripheral Blood Monocyte-Derived Dendritic Cells in Patients with Bladder Cancer
by  Xianglong Li, Shixiu Shao, Liran Zhai, Xuewen Guo, Haitao Niu, Yonghua Wang
Cancer Cell Research 2016 3(12) 286-289; published online 22 Octber 2016
Abstract: To investigate B7-H1 expressions on peripheral blood monocyte-derived dendritic cells (DCs) in patients with bladder cancer and the effect of B7-H1 blockade on DCs function. Monocyte-derived DCs (MoDCs) were generated from peripheral blood mononuclear cells, which were obtained from 30 patients with bladder cancer and 10 healthy donors as controls. The expressions of B7-H1 on MoDCs and PD-1 on CD8+T cells were analyzed by flow cytometry. The effects of B7-H1 blockade on MoDCs capacity of stimulating T-cell proliferation and producing IL-10 and IL-12 were detected by mixed lymphocyte reaction and ELISA respectively. Compared with control, the capacity of MoDCs stimulating T-cell proliferation was significantly decreased in patients with bladder cancer. B7-H1 and PD-1 expressions were significantly up-regulated on MoDCs and CD8+T cells respectively in patients with bladder cancer. Moreover, pre-incubation MoDCs with B7-H1 blocking mAb to block B7-H1 pathway resulted in a significant increase in T-cell stimulated proliferation and IL-12 secretion, while a significant decrease in IL-10 secretion. B7-H1 up-regulation may contribute to the functional deficiency of DCs in patients with bladder cancer, while B7-H1 blockade can restore and enhance DCs function in patients with bladder cancer.

Open Access Download (free) PDF


Article: Research of Expression about HIF-1α in Non-Hodgkin's Lymphoma in Children and Its Influence to Prognosis and Chemotherapy Sensitivity
by  Xilin Xiong, Chaotao Zeng, Ling Liu
Cancer Cell Research 2016 3(12) 290-293; published online 22 Octber 2016
Abstract: To explore the expression of (hypoxia-inducible factor-1α (HIF-1α) in Non-hodgkin's lymphoma in children and its influence in prognosis and sensitivity to chemotherapy. We conducted immunohistochemistry to determine the expression of HIF-1α in 125 cases of Non-hodgkin's lymphoma, and then investigated the correlation between the expression level of HIF-1α and the effect of preoperative chemotherapy, or 5-year survival rate. HIF-1α was highly expressed in Non-hodgkin's lymphoma, and was unrelated to Gender, ECOG (Eastern Cooperative Oncology Group) and IPI (international prognostic index)score of tumor (P>0.05), but related to TNM clinical stage, B symptoms, LDH level (P<0.05) . The efficiency of chemotherapy in HIF-1α negative patients (90%) was significantly higher (P<0.05) than that of HIF-1α positive patients (68.75%). HIF-1α was highly expressed in Non-hodgkin's lymphoma, and was closely related to lymph node metastasis, prognosis, and sensitivity to chemotherapy. So, HIF-1α could be one of the indicators that evaluate the prognosis and effectiveness of chemotherapy in child with Non-hodgkin's lymphoma.

Open Access Download (free) PDF


Article: The Influences of Chemotherapeutics on the Cell Cycle in SK-N-SH Neuroblastoma Cells and Clinic Significance
by  Xilin Xiong, Ling Liu, Kai Qi, Chi Zhang, Yueqin Chen, Yang Li
Cancer Cell Research 2016 3(12) 294-298; published online 22 Octber 2016
Abstract: This study was aimed to confirm the drug influence on cell cycle of SK-N-SH cells by flow cytometry analysis. The SK-N-SH cells were divided into two groups including Treatment group and control group. All of them were given chemotherapy drugs of ADM, CTX, VP16 and VCR, and then detected the influences of chemotherapy drugs on the cell cycle of SK-N-SH cells by flow cytometry instrument and. ADM: The percentage of G0/G1 phase of experimental group is (51.41±0.13)%, the percentage of G0/G1 phase of control group is (16.59±0.52)%. CTX:The percentage of G0/G1 phase of experimental group is (35.19±0.69)%, the percentage of G0/G1 phase of control group is (9.03±0.21)%. VP16:The percentage of G0/G1 phase of experimental group is (50.25±2.06)%, the percentage of G0/G1 phase of control group is (19.33±1.12)%. DDP:The percentage of G0/G1 phase of experimental group is (25.24±0.37)%, the percentage of G0/G1 phase of control group is (13.51±0.39)%. After treated with ADM, CTX, VP16 and DDP, the cell number of G0/G1 phase is more than control group in SK-N-SH cells, this showed significant difference (P<0.01). VCR:The percentage of G2/M phase of experimental group is (45.76±0.39)%, the percentage of G2/M phase of control group is (10.95±0.36)%. The cell number of G2/M phase is more than control group in SK-N-SH cells, this showed significant difference (P<0.01). ADM, CTX, VP16 and DDP can significantly arrest cell in G0/G1 phase, while VCR can significantly arrest cell in G2/M phase.

Open Access Download (free) PDF


Article: Influencing Factor Analysis on Initial Poor Graft Function after Liver Transplantation
by  Ran Tao, Bin Zhang
Cancer Cell Research 2016 3(12) 299-306; published online 7 November  2016
Abstract: To analyze the related influencing factors for initial poor graft function (IPGF) after liver transplantation (LT). 107 cases underwent liver transplantation from March in 2014 to November in 2015 were selected randomly. The group of IPGF is confirmed if ALT and/or AST are above 1500IU/L, while non-IPGF below 1500IU/L within 72h after LT. The donor related influencing factors includes age, source, warm ischemic time, cold preservation time, liver biopsy at the end of cold ischemia and if there is a supplementary perfusion at the end of cold ischemia. The recipient related influencing factors includes gender, age, primary liver diseases, Child-Pugh classification, MELD score and ECOG score. The postoperative related influencing factors include intubation time and ICU monitoring time. There are 31 cases (28.97%) in IPGF group and 67 cases (71.03%) in non-IPGF group. The result of ALT and/or AST are significantly higher in IPGF group than those in non-IPGF group (P<0.05). The recovery time of liver function is significantly longer in IPGF group (20.50±5.28d) than that in non-IPGF group (13.20±5.50d) (P<0.01). The donor warm ischemic time is significantly longer in IPGF group (4.34±2.25min) than that in non-IPGF group (2.18±1.90min) (P<0.05). The cold preservation time were significantly longer in IPGF group (9.73±1.19h) than that in non-IPGF group (9.24±0.99h) (P<0.05). There was significant difference between the 2 groups in spite of higher values in Child-Pugh C recipients’ ratio. There were no significant differences between the 2 groups (P>0.05). The rest of related influencing factors had no significant differences between the 2 groups. Longer donor warm ischemic time, cold preservation time and Child-Pugh C recipients’ ration are important risks factors for IPGF. Longer anhepatic time and rewarm ischemic time are the potential risk factors.

Open Access Download (free) PDF


 

 
��ҳģ��